Pomalidomide
Aliases
4-Aminothalidomide, Actimid, CC4047, CC-4047, Imnovid (2 other aliases)
58 clinical trials
3 abstracts
32 indications
Indication
Waldenstrom MacroglobulinemiaIndication
Multiple MyelomaIndication
Relapsed Multiple MyelomaIndication
Multiple Myeloma in RelapseIndication
Diffuse Large B-cell LymphomaIndication
Non-Hodgkin lymphomaIndication
Burkitt lymphomaIndication
Plasmablastic LymphomaIndication
B-cell NeoplasmIndication
Viral Associated MalignanciesIndication
Kaposi SarcomaIndication
LymphomaIndication
Systemic amyloidosisIndication
Relapsed CancerIndication
Plasma Cell LeukemiaIndication
PlasmacytomaIndication
HIV-1 PositiveIndication
RelapseIndication
RefractoryIndication
AgingIndication
ComorbidityIndication
Smoldering Plasma Cell MyelomaIndication
Acute Myeloid LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Myelodysplastic SyndromeIndication
Myeloproliferative NeoplasmIndication
AmyloidosisIndication
Diffuse Large B-Cell LymphomaIndication
Smith-Magenis SyndromeIndication
AmyloidIndication
AL AmyloidosisIndication
AL amyloidosisClinical trial
Phase I Study of Pomalidomide in Relapsed or Refractory Waldenstrom MacroglobulinemiaStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2022-09-29
Abstract
Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,
Clinical trial
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Phase I Study of Pomalidomide and Nivolumab in Patients With Virus-Associated Malignancies With or Without HIVStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Maintenance Therapy With Carfilzomib, Pomalidomide and Dexamethasone (CPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-InStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
Phase 1/2 Trial of Selinexor in Combination With Pomalidomide and Dexamethasone ± Carfilzomib for Patients With Proteasome-Inhibitor and Immunomodulatory Drug Refractory Multiple Myeloma (SCOPE)Status: Recruiting, Estimated PCD: 2025-03-04
Clinical trial
A Study of Bortezomib, Pomalidomide, Dexamethasone in Patients With Systemic AL AmyloidosisStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi SarcomaStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell LeukemiaStatus: Completed, Estimated PCD: 2020-10-30
Clinical trial
A Phase II Multicenter Study of Pomalidomide Monotherapy in HIV-Positive Individuals With Kaposi Sarcoma (KS) in Sub-Saharan Africa (SSA)Status: Active (not recruiting), Estimated PCD: 2024-11-29
Clinical trial
Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2028-12-28
Clinical trial
Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study)Status: Active (not recruiting), Estimated PCD: 2022-04-29
Clinical trial
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2026-04-10
Clinical trial
Evaluating Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current TherapyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-11-30
Clinical trial
Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in Patients With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody TherapyStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Single-Arm Phase II Study of Isatuximab With Carfilzomib and Pomalidomide in Relapsed or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2026-04-15
Clinical trial
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1Status: Recruiting, Estimated PCD: 2025-11-03
Clinical trial
Phase I/II Study of Ixazomib in Combination With Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients With Double Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2028-07-01
Clinical trial
Randomized Phase 2 Study of Daunorubicin and Cytarabine Liposome + Pomalidomide Versus Daunorubicin and Cytarabine Liposome in Newly Diagnosed AML With MDS-Related ChangesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)Status: Completed, Estimated PCD: 2022-02-27
Clinical trial
Desensitization of Immunomodulating Agent-Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTSStatus: Completed, Estimated PCD: 2015-07-01
Clinical trial
Phase 2 Trial of Induction With Ixazomib, Pomalidomide, Dexamethasone Prior to Salvage Autologous Stem Cell Transplant Followed by Consolidation With Ixazomib, Pomalidomide, and Dexamethasone and Ixazomib Maintenance in Multiple MyelomaStatus: Completed, Estimated PCD: 2021-04-13
Clinical trial
Maintenance Therapy With Belantamab, Pomalidomide and Dexamethasone (BPd) in High-Risk Myeloma Patients: A Phase 2 Study With a Safety Run-InStatus: Recruiting, Estimated PCD: 2024-10-21
Clinical trial
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate ConsortiumStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Prospective Exploratory Clinical Study of Orelabrutinib, Pomalidomide, Rituximab Combined With miniCHOP-like Regimen in Treatment-naive Elderly Patients With DLBCLStatus: Recruiting, Estimated PCD: 2025-07-03
Clinical trial
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to DaratumumabStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Selinexor in Combination With Immunomodulator to Treat Relapsed/Refractory Multiple Myeloma PatientsStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and LenalidomideStatus: Recruiting, Estimated PCD: 2025-10-14
Clinical trial
Isa-CAPED MM: Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone (Isa-KPd) for Patients With Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-12-20
Clinical trial
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-07-02
Clinical trial
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of TherapyStatus: Recruiting, Estimated PCD: 2026-02-06
Clinical trial
A Phase 2 Study With Safety Run-In of Marizomib, Pomalidomide, and Dexamethasone For Relapsed and Refractory Multiple Myeloma and CNS MyelomaStatus: Not yet recruiting, Estimated PCD: 2025-12-02
Clinical trial
Daratumumab, Pomalidomide and Dexamethasone for Del(17p) Positive Relapsed and Relapsed/Refractory Multiple Myeloma Patients [DEDALO]Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-09-09
Clinical trial
A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension StudyStatus: Recruiting, Estimated PCD: 2026-01-30
Clinical trial
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and LenalidomideStatus: Recruiting, Estimated PCD: 2026-04-23
Clinical trial
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Abstract
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.Org: University College London Cancer Institute, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Medical College of Wisconsin, Peter MacCallum Cancer Centre, Melbourne, Australia, Hematology Clinic,
Abstract
Effect of autologous lymphocytes combined with chemotherapy as the first-line treatment of advanced gastric cancer.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Clinical trial
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm StudyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple MyelomaStatus: Recruiting, Estimated PCD: 2027-08-01